Introduction
Lacosamide, a novel anti-epileptic drug (AED) that enhances the slow inactivation of voltage-gated sodium channels, is widely used to treat seizures associated with focal onset epilepsy. Common adverse effects of lacosamide include dizziness, vertigo, ataxia, and diplopia [1] .
HyperCKemia is one of the characteristics of rhabdomyolysis typically resulting from the destruction of muscle cells, leading to the leakage of potentially toxic cellular contents into the systemic circulation [2] . HyperCKemia associated with some AEDs has been reported [3] ; however, to date, no cases of hyperCKemia or rhabdomyolysis associated with lacosamide have been reported. In this report, we describe the case of an elderly patient with focal onset epilepsy who developed hyperCKemia after lacosamide administration, which resolved after lacosamide discontinuation.
Case report
A 72-year-old man was admitted to our hospital with a 7-year history of nocturnal occurrence of sudden-onset lower limb hyperactivity, which never occurred while he was awake. He had no family history of neuromuscular diseases. He had been taking alfacalcidol for osteoporosis, and silodosin and cernitin pollen extract for prostatomegaly for more than 1 year. Video-electroencephalogram monitoring revealed seizure activity, accompanied by the placement of both hands behind his head, laughter, and repetitive up and down movement of both lower limbs during the non-REM stage of sleep. The electroencephalograph during the attack showed a leading spike in the right hemisphere (maximum right frontal-central region) followed by bilateral diffuse attenuation, and eventually, post-ictal slowing in the right frontal region. During the interictal state, epileptiform discharges and intermittent slow waves were observed in the right anterior-middle temporal and right frontal-central regions, respectively. Magnetic resonance imaging showed no abnormalities indicative of epileptogenic lesions. Single photon emission computed tomography imaging of dopamine transporters showed normal high-density radioactive uptake in the striatum. He was therefore diagnosed with focal onset epilepsy. Lacosamide was started at 50 mg/day and then increased to 100 mg/ day for the subsequent 8 days, resulting in a decrease in seizure frequency to once every 3-4 days. Although his serum creatine kinase (CK) level was within the reference range before and 7 days after lacosamide initiation, it increased to 1868 U/L (reference range: 62-287 U/L) on the 15th day after LCM initiation ( Fig. 1 ; CK-MB, 30 U/L). The white blood cell (WBC) count and ratio of eosinophils was within the reference range (WBC: 4940/μl and eosinophils: 2.8%). Other notable laboratory findings were as follows: aspartate transaminase (AST), 51 U/L (reference range: 13-33 U/L) and lactate dehydrogenase (LDH), 309 U/L (reference range: 62-287 U/L). We stopped lacosamide and initiated levetiracetam at 500 mg/day, but discontinued it after 1 day because the patient complained of dizziness. The patient reported no excessive exercise, trauma, skin rash, fever, muscle weakness, myalgia, or dark urine during LCM administration. No convulsive seizures were verified by his wife sleeping besides him. Neurological examination revealed no muscle weakness. Examinations of serum thyroid hormone levels and autoimmune screening tests evaluating the presence of antinuclear antibodies, anti-ribonucleoprotein antibodies, and anti-Jo1 antibodies revealed no abnormalities. Urinalysis and microscopy results were normal. HyperCKemia caused by rhabdomyolysis that was associated with LCM therapy was suspected. His serum CK gradually decreased and returned to normal after lacosamide discontinuation ( Fig. 1 ). About 2 weeks after lacosamide discontinuation, his wife observed a new-onset focal to bilateral tonic-clonic seizure with urinary incontinence, and his serum CK level increased to 868 U/L. We restarted levetiracetam treatment at 250 mg/day, and his seizure frequency decreased to once every 3 days, without any levetiracetam-associated adverse effects.
Discussion
Rhabdomyolysis has a wide variety of clinical manifestations, ranging from only asymptomatic hyperCKemia to serious complications such as acute renal failure, cardiac arrhythmia, and disseminated intravascular coagulation [3] . Our patient showed asymptomatic hy-perCKemia that occupied almost skeletal muscle cells, which was concordant with rhabdomyolysis. Many causes of rhabdomyolysis have been identified, including inherited metabolic myopathies, status epilepticus, trauma, medication, and endocrine disorders such as hyperthyroidism or hypothyroidism [2] . At first, we considered the rhabdomyolysis in our patient to be caused by epileptic seizures themselves. However, despite the daily occurrence of seizures, his serum CK level was within the reference range, and the seizure frequency decreased after LCM administration. Furthermore, no focal to bilateral tonic-clonic seizure was detected by his wife during LCM administration, although the possibility of unobserved convulsion seizure could not be completely excluded. In addition, a rapid decline in serum CK levels was observed after LCM discontinuation. Thus, there were no evident explanations for hyperCKemia, and a close temporal relationship was observed between LCM exposure and hyperCKemia. Therefore, we concluded that the hyperCKemia was induced by LCM administration. Early recognition and management of the hyperCKemia might be another explanation for the hyperCKemia without other clinical symptoms.
AED-associated rhabdomyolysis is a rare condition with a low incidence rate. AEDs associated with rhabdomyolysis include levetiracetam, phenytoin, valproate, gabapentin, and lamotrigine [3] . Among these AEDs, LCM acts as well as phenytoin and lamotrigine selectively on voltage-gated sodium channels. The cause of hyperCKemia associated with voltage-gated sodium channel blockers could be drug-induced hypersensitivity syndrome and overdose use [3] ; however, hy-perCKemia induced by hypersensitivity syndrome in our patient is improbable because of his clinical symptoms and laboratory results. In addition, CK was elevated at not LCM overdose, but at low-dose LCM. As the hyperCKemia appeared at the dose-up stage of LCM therapy, it could be dose-dependent. A common pathomechanism of AED-induced rhabdomyolysis has not been reported. We hypothesise that LCM might inhibit intracellular mitochondrial ATP production, disrupt Ca 2+ homeostasis in muscle cells, or directly disturb muscle cell membrane function or structure [4] , leading to rhabdomyolysis. Further studies are necessary to verify the pathophysiology and dose-dependency of hyperCKemia induced by LCM.
Conclusions
HyperCKemia is a possible adverse effect associated with LCM administration, although its pathomechanism remains to be elucidated. Because hyperCKemia has potentially serious complications, particularly in elderly patients with age-related physiological alterations, clinicians should be aware of the possibility of LCM-associated hyperCKemia and closely monitor serum CK levels after LCM administration.
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